Obstructive Lung Disease
-
Rethinking pediatric home mechanical ventilation
Persistent disparities in caregiver burden, home nursing shortages, and access to resources highlight the need for standardized education, telemedicine integration, and national safety infrastructure.
-
Triple therapy shows meaningful benefits in uncontrolled asthma
Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.
-
Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD
Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.
-
Study finds triple combination modulator therapy reduces inflammation in CF
Valentino Bezzerri, PhD, discusses findings from a compassionate-use study examining the effects of elexacaftor/tezacaftor/ivacaftor on inflammation in patients with cystic fibrosis.
-
Effects of LAMA or ICS withdrawal may increase risk for COPD exacerbations
Discontinuing LAMA or ICS treatment may more than double the risk of exacerbations for up to 90 days, according to an analysis by Alexander Mathioudakis, MD, PhD.
-
RSV hospitalization increases cardiorespiratory event, COPD exacerbation risk
Caihua Liang, MD, PhD, and Elizabeth Begier, MD, discuss the importance of prevention in light of data showing elevated risk for up to 180 days following the acute infection.
-
Airway clearance pharmacotherapy: Past, present, and future
The central question in non-CF bronchiectasis is no longer whether mucoactives work but for whom, under what circumstances, and at what cost in treatment burden.
-
Biologic therapies in asthma: From foundation to the future
Biologic therapies are changing severe asthma management, shifting the goal from control to remission. Diego J. Maselli, MD, FCCP; Dharani Narendra, MD, FCCP; and Megan Conroy, MD, MAEd, FCCP, explore their impact in this installment of Clinical Outlook in Pulmonology.
-
Intranasal saline improves symptoms in children with sleep-disordered breathing
The results of the MIST+ trial support the conclusion that saline is as effective as corticosteroid in managing symptoms of OSDB, said lead author Gillian Nixon, MD.
-
Adult bronchiectasis guidelines updated to reflect emerging evidence on disease identification and management
New bronchiectasis recommendations from the European Respiratory Society reflect a shift toward individualized, risk-based care, recognizing diverse inflammatory and microbiologic profiles. The guidelines emphasize early identification of high-risk patients, multidimensional assessment, and universal airway clearance training.
-
Data support use of nirsevimab prophylaxis to reduce RSV hospitalization risk for infants
Retrospective data show significantly fewer infants were hospitalized for RSV after nirsevimab became available. Among the RSV hospitalizations that occurred during that time period, 75% were in infants who had not received nirsevimab.
-
While still elevated, early 2026 data show US influenza A cases stabilizing or decreasing
Infectious disease expert Frederick G. Hayden, MD, said timely use of antivirals for prophylaxis and treatment can minimize the impact of this flu season, which has seen a significant mismatch between vaccines and the circulating strain.
